Track 07 of 9
Pediatric Gastroenterology
Pediatric IBD, celiac disease and feeding disorders.
Pediatric GI is increasingly aligned with adult therapeutic advances while preserving developmental and growth-specific endpoints. Pediatric IBD now uses ustekinumab, vedolizumab, risankizumab, and upadacitinib with weight-based dosing supported by PK extrapolation studies. Eosinophilic esophagitis management has been transformed by dupilumab (FDA-approved down to age 1), with budesonide oral suspension as a steroid-sparing option. Celiac screening strategies, gluten challenge protocols, and the role of HLA-DQ2/DQ8 are revisited. Sessions also address pediatric MASLD, ARFID and feeding disorders, intestinal failure with teduglutide, and very-early-onset IBD genetic workup (IL10RA, XIAP).
Focus areas
- Pediatric IBD: weight-based biologics and small-molecule extrapolation
- Eosinophilic esophagitis: dupilumab and budesonide oral suspension
- Very-early-onset IBD: monogenic workup (IL10R, XIAP, CYBB)
- Pediatric MASLD: lifestyle, vitamin E and emerging pharmacotherapy
- Intestinal failure and short bowel: teduglutide and autologous reconstruction
- Avoidant/restrictive food intake disorder (ARFID) and feeding clinics
- Transition of care from pediatric to adult IBD programs